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Abstract. – State of the Art: Gastric can-
cer (GC) is still a major health problem world-
wide due to its frequency, poor prognosis and
limited treatment options. At present prevention
is likely to be the most effective means of reduc-
ing the incidence and mortality from this dis-
ease. The most important etiological factors im-
plicated in gastric carcinogenesis are diet and
Helicobacter pylori (H. pylori) infection. 
High intake of salted, pickled or smoked foods,
as well as dried fish and meat and refined carbohy-
drates significantly increased the risk of develop-
ing GC while fibers, fresh vegetables and fruit were
found to be inversely associated with GC risk. 
Epidemiological investigations (retrospective,
case-control and prospective) and several meta-
analyses have demonstrated that concurrent or
previous H. pylori infection is associated with an
increased risk of GC in respect to uninfected peo-
ple. H. pylori colonizes gastric mucosa where it
induces a complex inflammatory and immune re-
action that on time leads to a severe mucosal
damage i.e., atrophy, intestinal metaplasia (IM)
and dysplasia. The risk of GC is closely related to
the grade and extension of gastric atrophy, IM
and dysplasia. 
Perspectives and Conclusions: Today a plausi-
ble program for GC prevention means: (1) a correct
dietary habit since childhood increasing vegeta-
bles and fruit intake, (2) a decrease of H. pylori
spread improving family and community sanitation
and hygiene, (3) a search and treat H. pylori strate-
gy in offspring of GC, (4) a search and treat H. py-
lori strategy in patients with chronic atrophic gas-
tritis and intestinal metaplasia (IM), (5) a careful en-
doscopic and histologic follow-up if precancerous
lesions persist irrespective of H. pylori eradication.
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Introduction
Gastric cancer (GC) is still a major health
problem worldwide due to its frequency, poor
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prognosis and limited treatment options. Current-
ly, the 5-year-relative survival rate is about 20%.
According to the International Gastric Cancer
Society, more than 800,000 people are affected
by GC every year and up to 650,000 people have
succumbed to gastric cancer1. It is likely that in
2020 GC will increase by 10% in developing
countries2. 
At present, primary (addressing etiological
factors) and secondary (addressing patients at
risk) prevention are likely to be the most effec-
tive means of reducing the incidence and mortali-
ty from this disease. 
GC is a multifactorial disease resulting from
an interplay between host genetic susceptibility
and environmental factors3. 
Genetic susceptibility play a trivial role in
the pathogenesis of this condition accounting
for about 1% of all GCs. Microsatellite insta-
bility and E-cadherin are the most frequent ge-
netic alterations associated with a family histo-
ry of GC (more than two relatives in two suc-
cessive generation)4. At present the Interna-
tional Gastric Cancer Consortium recommends
prophylactic gastrectomy in carriers of E-cad-
herin germline mutation belonging to familial
GC5.
Studies of migrants moving from a high- to a
low risk area have shown that the migrants ac-
quire the cancer pattern of the host country with-
in a single generation suggesting that environ-
mental factors play a trigger role in the carcino-
genic process6. The most important environmen-
tal factors implicated in gastric carcinogenesis
are diet and Helicobacter pylori (H. pylori) in-
fection. 
Diet
Diet, to which we are necessarily exposed
every day, can either inhibit or induce carcino-
genic process: high intake of salted, pickled or
smoked foods, as well as dried fish and meat and
refined carbohydrates significantly increased the
risk of developing GC while fiber, fresh vegeta-
bles and fruits were found to be inversely associ-
ated with GC risk7-11. 
High consumption of refined carbohydrates
has been shown to be associated with a signifi-
cant increased risk of developing GC with an es-
timated Odds ratio (OR) ranging from 1.512 to
8.73 per 100 mg of daily intake13. High con-
sumption of saturated fat and cholesterol en-
hanced the risk of cancer for intestinal type GC
(OR Q4 vs Q1 4.37; 95% CI 1.89-10.12 for satu-
rated fat and OR Q4 vs Q1 2.39; 95% CI 1.23-
4.64 for cholesterol)11. Analysis of the data ob-
tained in 21 studies involving a total of 1,651,231
individuals, followed for periods ranging be-
tween 3.3 and 25 years, substantially confirmed
the significant increased risk of developing GC
due to high intake of total carbohydrates, salted
fish, processed meat, refined grains and saturated
fat14. A large prospective study on diet and can-
cer carried out on 521,457 individuals aged 35-
70 years recruited in 10 European countries
(EPIC – European Prospective Investigation into
Cancer and Nutrition study), by analysing 314
incident cases of GC that had occurred after 6.6
average years of follow-up, reported a significant
increase of non-cardia GC risk associated with
intake of total meat (calibrated hazard risk [HR]
100 g/day increase 3.52; 95% CI 1.96-6.34), red
meat (calibrated HR per 50 g/day increase 1.73;
95% CI 1.03-2.88), and processed meat (calibrat-
ed HR per 50 g/day increase 2.45; 95% CI 1.43-
4.21). The endogenous formation of nitroso com-
pounds (ENOC) was significantly associated
with non-cardia cancer risk (HR 1.42; 95% CI
1.14-1.78 for an increase of 40 mg/day) especial-
ly in those cases with H. pylori infection (p for
interaction = 0.09)15. 
The beneficial effect of fresh fruit and vegeta-
bles on the mucosa of the gastrointestinal tract is
mainly the consequence of anti-oxidant proper-
ties of micronutrients whose intake inversely cor-
related with the risk of GC16-18. Correa et al19
have shown that dietary supplementation with
anti-oxidant micronutrients, such as ascorbic acid
or beta-carotene, in a GC high-risk population,
significantly increased the rate of regression of
cancer precursor lesions to a similar extent as
that observed with H. pylori eradication. Consid-
erable evidence supports the hypothesis that
flavonoids and other polyphenolic phytochemi-
cals contained in certain foodstuffs, for example
onions, red grapes, nuts, and green tea, mediate,
or contribute to the putative cancer chemopreven-
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tive properties of their dietary sources. Their
ability to reduce cancer incidence in population
studies is likely related to their ability to induce
apoptosis and inhibit neaongiogenesis20-23. Also,
extra-virgin olive oil component, oleocanthal, has
been demonstrated to exert ibuprofen-like activi-
ty being able to significantly inhibit cyclooxyge-
nase activity24. A recent study has shown that
polyphenol extracts obtained from apple prevent
reactive oxygen species (ROS) and in-
domethacin-induced injury to gastric epithelial
cells in vitro and to the rat stomach in vivo and
this effect is mediated by the anti-oxidant activity
of catechin and chlorogenic acid25. 
Helicobacter Pylori Infection
Helicobacter pylori is one of the most frequent
infection affecting more than 50% of the world-
wide population. Most infected individuals have
a symptomatic chronic gastritis, a subgroup pep-
tic disease and a small minority develops GC
(lifetime risk, 0.1%)
Exposure of gastric epithelial cells to H. pylori
results in a complex inflammatory and immune
reaction with the generation of ROS and in-
creased levels of nitric oxide synthase which in
turn can induce oncogene activation and onco-
suppressor gene inactivation and ultimately GC
development26. 
The extent and severity of gastric mucosal in-
flammation, as well as the clinical outcome of
the infection, depend on a number of factors in-
cluding the virulence of the bacterium, host ge-
netic susceptibility, immune response, age at the
time of initial infection and environmental fac-
tors27. Epidemiological investigations (retrospec-
tive, case-control and prospective) and several
meta-analyses have demonstrated that concurrent
or previous H. pylori infection is associated with
an increased risk of GC in respect to uninfected
people (OR 3.0; 95% CI 2.3-3.8); the risk was
stronger when the infecting H. pylori strain was
CagA-positive and blood samples for H. pylori
serology were collected ten years before cancer
diagnosis (OR 5.9; 95% CI 3.4-10.3)28.
Helicobacter pylori, indeed, is characterized
by several putative virulence factors, i.e., vacA,
iceA, and particularly cagA, with the cag patho-
genicity island (PAI), that are variously associat-
ed with the risk of gastric disease29. 
The vacA gene, which encodes a vacuolating
cytotoxin and is present in ∼50% of H. pylori
isolates comprises two variable regions: the s re-
gion (s1a, s1b, s1c, or s2 allele), and the m re-
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gion (m1, m2a, or m2b allele)30. The vacAs1 and
vacAm1 strains appear to be more virulent than
type s2 strains, presenting a higher degree of in-
flammation and higher risk for peptic ulcer dis-
ease, gastric atrophy, and GC31.
The cagA gene is a marker for the presence of
the PAI32. Only one-half of Western isolates car-
ry the cag PAI, whereas nearly all East Asian
strains carry the cag PAI33. Infection with cagA-
positive H. pylori strains is associated with high-
er levels of mononuclear and neutrophilic infil-
trates, more severe atrophy, intestinal metaplasia
and alterations in the gastric epithelial cell cy-
cle34. Pooled data have shown that cagA positive
strains of H. pylori are associated with a higher
risk of GC (OR 2.01; 95% CI 1.21-3.32) in re-
spect to cagA negative strains35. Two studies
conducted in the United States and one in Japan
have shown that the cagA-positive strain was
more closely related to intestinal type GC than
the cagA-negative strain36-38. A large population-
based case-control study from Los Angeles
County confirmed this positive association39.
However, currently, the presence of a functional
cagA pathogenicity island has no predictive val-
ue for the presence or future development of a
clinically significant outcome40. Therefore, the
question of whether certain H. pylori strains are
more carcinogenic than others still remains to be
elucidated and may vary in relation to the differ-
ent geographical areas. 
Genetic Factors
Early studies41 revealed that GC was less com-
mon in patients with blood group 0, but was fre-
quently associated with blood group A which in-
creases the risk by 16-20%42. A positive family
history of GC has been associated with an in-
creased (~three-fold) risk of GC43. Interestingly,
subjects with both a positive family history and
infection with cagA-positive H. pylori strains had
a 16-fold increased risk of non-cardia GC44. 
Polymorphisms in a wide variety of genes,
present in a significant proportion of the normal
population, may affect the activity of key inflam-
matory molecules and modify the effect of envi-
ronmental exposures. Thus, gene-environmental
interactions could explain the high inter- individ-
ual and/or geographic variations in the GC inci-
dence. Interleukin (IL)-1beta and IL-1 receptor
antagonists (IL-1ra) are potent cytokines that
play a key role in regulating gastric acid secre-
tion, showing a 100-fold greater potency than
proton pump inhibitors45. An important case-con-
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trol study conducted in Scotland and Poland
showed that individuals with particular IL-1beta
gene polymorphism presented an increased risk
of GC in the presence of H. pylori infection46. 
A variety of associations between GC risk, H.
pylori infection, and specific HLA alleles have
been described. In a case-control study in the
United States, the HLA-DQB1*0301 as well as
the HLA-DRB1*1601 alleles were more com-
mon in GC than in controls (OR 3.2)47. Another
case-control study suggested that the absence of
HLA-DQA1*0102 may be a host genetic risk
factor for H. pylori infection and the intestinal
type GC48. An European study has confirmed
absence of the HLA-DQA1*0102 allele as a
risk factor for H. pylori infection, but it did not
find any association with GC risk49. Taken to-
gether, these results appear to indicate the exis-
tence of a variable genetic susceptibility that
may confer differential risk for H. pylori infec-
tion and GC. Cohort studies, taking into account
both the different genetic and environmental
factors, are needed to establish not only the rel-
ative contribution of these factors to tumour de-
velopment but also the contribution of their pu-
tative interaction. 
Age
It has been proposed that age at the time of on-
set of H. pylori infection may be another deter-
minant of disease outcome27. Onset of H. pylori
infection early in life has been associated with an
increased risk of GC36. Epidemiological studies
have revealed a high incidence of adult GC in ar-
eas with a high prevalence of H. pylori infection
in childhood35,50,51. In the younger Japanese gen-
eration, a OR 13.3 was shown for the relation-
ship between H. pylori infection and GC52. 
Gastric cancer tends to occur in older people
and it seems more likely to occur in a stomach
that has been inflamed for many years. Indeed,
continuous infection with H. pylori during child-
hood, or the teenage years, may induce in adult-
hood irreversible harm to the gastric mucosa53.
Therefore, it is mandatory that H. pylori be eradi-
cated in childhood or early teens, since eradica-
tion after the irreversible gastric mucosa lesions
have been inflicted, does not prevent carcinogen-
esis at all. In a prospective, randomized, placebo-
controlled study carried out in 1,630 subjects
showed that there was no significant difference
concerning GC incidence between patients treat-
ed or not treated with H. pylori eradication thera-
py. However, if the Authors initially excluded pa-
tients with atrophy or intestinal metaplasia (IM),
expression of a long-standing infection, the dif-
ference was significant (p<0.02)54.
Precancerous Lesions
The secondary prevention focuses on patients
at risk of developing GC. Gastric atrophy, in-
deed, is considered the first relevant step in the
histogenesis of intestinal type GC according to
the multistep process suggested by Correa55. In
fact, the risk of GC is closely related to the grade
and extension of gastric atrophy being up to 80-
90 folds higher in respect to the general popula-
tion in patients with severe atrophy involving
both antrum and body56. Gastric atrophy assumes
a precancerous meaning particularly when it is
located or extended in the corpus. This latter con-
dition, indeed, damaging parietal cells decreases
the acidity in the stomach and provokes the trans-
formation of nitrates food components in nitrites
and nitrosamides which are critical for the onset
of the gastric carcinogenic process. This hypoth-
esis links the theory of “N-nitroso compounds-
mediated GC risk” with that of “H. pylori-related
GC risk” suggesting an “integrated model” of
gastric carcinogenesis57. 
Chronic atrophic gastritis is often associated
with IM, the subsequent step in the Correa model
of H- related gastric carcinogenesis55,58,59. The
prevalence of IM was significantly higher in H.
pylori-positive (43%) than in H. pylori-negative
subjects (6.2%)60. 
Intestinal metaplasia has been classified ac-
cording to Jass and Filipe as complete or type I,
or incomplete which comprises types II and III61.
Based on retrospective data, the risk of GC is re-
lated to the type of IM56. In a 10-year follow-up
study from Slovenia, patients with IM showed an
overall 10-fold increased risk of GC compared
with those without IM62. In another study, the risk
of GC was four-fold higher in patients with IM
type III than in those with type I63. A Japanese
study reported that IM was the only criterion as-
sociated with the development of intestinal type
GC64.
The association between the risk of GC devel-
opment and IM subtypes is, however, not univer-
sally accepted. Cassaro et al65 have shown that
IM involving the lesser curvature, from the car-
dia to the pylorus, or the entire stomach, was as-
sociated with a higher risk of GC than focal or
antral predominant IM. Thus, the distribution of
IM rather than IM subtype may provide a higher
predictive value of cancer risk.
The next step in the cascade of morphological
changes in gastric carcinogenesis is dysplasia
that usually develops in the H. pylori infection,
atrophy and IM setting55. The development and
progression of dysplastic changes66 is clearly as-
sociated with H. pylori67. This process includes a
continuum of progressively dedifferentiated phe-
notypes which may result in a new cell. Accord-
ing to the definition of the World Health Organi-
zation, dysplasia is now called non-invasive gas-
tric neoplasia, indicating a pre-invasive neoplas-
tic change in the gastric glands68. The higher the
grade of dysplasia, the greater the risk of devel-
oping invasive GC69. 
The majority of carcinoma found in follow-up
studies and which were discovered within one
year of the diagnosis of dysplasia may indicate
that the carcinoma was already present at the
time of diagnosis of dysplasia66.
Conclusion
Today, GC remains a major clinical challenge
due to its frequency, poor prognosis and limited
treatment options. Therefore, one of the primaty
objective of World Health Organization and re-
searchers is to arrange programs for GC preven-
tion that means:
• A correct dietary habit increasing vegetable
and fruit intake since childhood;
• Decrease H. pylori spread improving family
and community sanitation and hygiene;
• Testing for E-cadherin germline mutations in
relatives of familial GC patients;
• Search and treat H. pylori in offspring of GC
patients;
• Search and treat H. pylori in patients with
chronic atrophic gastritis and IM and, if pre-
cancerous lesions persist, a careful endoscopic
and histologic follow-up have to be scheduled
irrespective of H. pylori eradication.
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